Syros Pharmaceuticals Statistics
Syros Pharmaceuticals (0S90) Stock Statistics & Valuation Metrics
Total Valuation
Syros Pharmaceuticals has a market cap or net worth of EUR 9,610.00. The enterprise value is EUR 86.52M.
- Market Cap
- EUR 9,610.00
- Enterprise Value
- EUR 86.52M
Share Statistics
Syros Pharmaceuticals has 26,832,457 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 26,832,457
- Owned by Insiders
- ―
- Owned by Institutions
- 0.53%
Financial Efficiency
Syros Pharmaceuticals’s return on equity (ROE) is -9.88 and return on invested capital (ROIC) is -91.82%.
- Return on Equity (ROE)
- -9.88
- Return on Assets (ROA)
- -0.98
- Return on Invested Capital (ROIC)
- -91.82%
- Return on Capital Employed (ROCE)
- -0.98
- Revenue Per Employee
- 146.12K
- Profits Per Employee
- -2.42M
- Employee Count
- 68
- Asset Turnover
- 0.06
- Inventory Turnover
- 0.00
Valuation Ratios
The current PE Ratio of Syros Pharmaceuticals is -0.00. Syros Pharmaceuticals’s PEG ratio is 0.00.
- PE Ratio
- -0.00
- PS Ratio
- 0.00
- PB Ratio
- 0.00
- Price to FCF
- -0.00
- Price to Operating Cash Flow
- -0.00
- PEG Ratio
- 0.00
Income Statement
In the last 12 months, Syros Pharmaceuticals had revenue of 9.94M and earned -164.57M in profits. Earnings per share was -5.81.
- Revenue
- 9.94M
- Gross Profit
- 7.68M
- Operating Income
- -128.99M
- Pretax Income
- -164.57M
- Net Income
- -164.57M
- EBITDA
- -157.19M
- Earnings Per Share (EPS)
- -5.81
Cash Flow
In the last 12 months, operating cash flow was -100.02M and capital expenditures -38,000, giving a free cash flow of -100.06M billion.
- Operating Cash Flow
- -100.02M
- Free Cash Flow
- -100.06M
- Free Cash Flow per Share
- -3.88
Dividends & Yields
Syros Pharmaceuticals pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -1024680.89%
- Earnings Yield
- -1452510.80%
Stock Price Statistics
- Beta
- -4.15
- 52-Week Price Change
- 0.00%
- 50-Day Moving Average
- 0.09
- 200-Day Moving Average
- 0.09
- Relative Strength Index (RSI)
- ―
- Average Volume (3m)
- ―
Important Dates
Syros Pharmaceuticals upcoming earnings date is ―, TBA (Not Confirmed).
- Last Earnings Date
- Nov 18, 2025
- Next Earnings Date
- ―
- Ex-Dividend Date
- ―
Financial Position
Syros Pharmaceuticals as a current ratio of 3.95, with Debt / Equity ratio of 372.55%
- Current Ratio
- 3.95
- Quick Ratio
- 3.95
- Debt to Market Cap
- 0.19
- Net Debt to EBITDA
- 0.49
- Interest Coverage Ratio
- -25.16
Taxes
In the past 12 months, Syros Pharmaceuticals has paid 0 in taxes.
- Income Tax
- 0
- Effective Tax Rate
- 0.00
Enterprise Valuation
Syros Pharmaceuticals EV to EBITDA ratio is 0.49, with an EV/FCF ratio of 0.70.
- EV to Sales
- -7.79
- EV to EBITDA
- 0.49
- EV to Free Cash Flow
- 0.70
- EV to Operating Cash Flow
- 0.71
Balance Sheet
Syros Pharmaceuticals has EUR 58.27M in cash and marketable securities with EUR 60.23M in debt, giving a net cash position of -EUR 1.95M billion.
- Cash & Marketable Securities
- EUR 58.27M
- Total Debt
- EUR 60.23M
- Net Cash
- -EUR 1.95M
- Net Cash Per Share
- -EUR 0.07
- Tangible Book Value Per Share
- -EUR 0.28
Margins
Gross margin is 77.33%, with operating margin of -1298.19%, and net profit margin of -1656.34%.
- Gross Margin
- 77.33%
- Operating Margin
- -1298.19%
- Pretax Margin
- -1656.34%
- Net Profit Margin
- -1656.34%
- EBITDA Margin
- -1582.08%
- EBIT Margin
- -1604.74%
